Stoke Therapeutics STOK 深 沪
已收盘 02-06 16:00:00 美东时间
32.40
+1.920
+6.30%
华盛通- 最 高33.48
- 今 开31.70
- 成交量 101.47万股
- 最 低 31.06
- 昨 收 30.48
- 总市值 18.51亿
- 52周最高 38.693
- 市盈率 静 --
- 换手率 1.78%
- 52周最低 5.35
- 委 比 -99.73%
- 总股本 5711.72万
- 历史最高 71.58
- 量 比 1.70
- 振 幅 7.94%
- 历史最低 3.35
- 每 手 1
- 风险率 9.64%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Stoke Therapeutics Signs Lease for New 98,500-Square-Foot Headquarters in Waltham
Stoke Therapeutics Signs Lease for New 98,500-Square-Foot Headquarters in Waltham Stoke Therapeutics Inc. has announced plans to relocate its headquarters to a new 98,500 square-foot facility at 245 Fifth Avenue in Waltham, Massachusetts. The move, set for late 2026 when the company’s current Bedfor
01-28 03:06
美股大行评级 | Medline获14家大行首予评级，最高目标价52美元；富国银行上调GOOGL目标价从268美元升至350美元
今日重点评级关注：HC Wainwright & Co.：维持Enlivex Therapeutics"买入"评级，目标价从7美元升至13美元；BTIG：维持Oruka Therapeutics"买入"评级，目标价从63美元升至73美元
01-13 10:18
Wedbush Maintains Outperform on Stoke Therapeutics, Raises Price Target to $36
Wedbush analyst Laura Chico maintains Stoke Therapeutics (NASDAQ:STOK) with a Outperform and raises the price target from $32 to $36.
01-12 21:56
Why Bark Shares Are Trading Higher By 20%; Here Are 20 Stocks Moving Premarket
Shares of Bark Inc (NYSE:BARK) rose sharply in pre-market trading after a 13D f...
01-12 17:34
美股大行评级 | 潜在涨幅36.7%！LMRI获多家大行首予超配评级； 瑞银下调甲骨文目标价从325美元至280美元
今日重点评级关注：HC Wainwright & Co.：维持Assertio Holdings"买入"评级，目标价从3美元升至35美元；HC Wainwright & Co.：维持万达生物制药"买入"评级，目标价从20美元升至22美元
01-06 17:52
Canaccord Genuity Maintains Buy on Stoke Therapeutics, Raises Price Target to $36
Canaccord Genuity analyst Sumant Kulkarni maintains Stoke Therapeutics (NASDAQ:STOK) with a Buy and raises the price target from $28 to $36.
01-05 20:10
美股大行评级 | 潜在涨幅113%！麦格理首予小马智行“跑赢大市"评级目标价29美元；Roth Capital下调好市多至"卖出"，目标价从906美元降至769美元
今日重点评级关注：HC Wainwright & Co.：维持BioCryst Pharma"买入"评级，目标价从30美元升至32美元；TD Cowen：上调Milestone Pharmaceuticals评级至"买入"，目标价8美元
2025-12-16 09:36
HC Wainwright & Co. Maintains Buy on Stoke Therapeutics, Raises Price Target to $50
HC Wainwright & Co. analyst Ananda Ghosh maintains Stoke Therapeutics (NASDAQ:STOK) with a Buy and raises the price target from $35 to $50.
2025-12-15 21:59
Stoke Therapeutics Highlights Zorevunersen’s Potential at Epilepsy Meeting
The latest announcement is out from Stoke Therapeutics ( ($STOK) ). At the 2025...
2025-12-05 22:28
Biogen And Stoke Therapeutics To Present Data From Studies Of Zorevunersen At 2025 AES Annual Meeting
Biogen Inc. (NASDAQ:BIIB) and Stoke Therapeutics, Inc. (NASDAQ:STOK), a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine, today announced data
2025-12-01 20:40
